Get the app
US › Healthcare

Atara Biotherapeutics Inc (ATRA)

US · Healthcare · Biotechnology

$9.71-3.96%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$630,000
Revenue YoY
-96.4%
Net profit
$-4.8M
Profit YoY
-302.5%
EPS
$-0.32
EPS estimate
$-0.35
Net margin
-767.3%

EPS came in at -0.32 against a street estimate of -0.35 — a beat of 8.6%.

Key statistics

Market cap
$99.3M
Forward P/E
18.9
P/B
16.14
Book value
$-3.92
EPS (TTM)
$-1.52
52-week high
$19.14
52-week low
$3.92
50-day MA
$9.08
200-day MA
$8.78
Beta
0.11

Analyst view

Analysts rate Atara Biotherapeutics Inc a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $13.67.

Shareholding

Insiders
16.80%
Institutions
57.67%

Largest institutional holders

FundStake
EcoR1 Capital, LLC15.46%
Adage Capital Partners Gp LLC8.47%
Redmile Group, LLC4.40%
Mackenzie Investments3.12%
Vanguard Capital Management, LLC2.17%
Point72 Asset Management, L.P.1.94%
Acadian Asset Management LLC1.30%
BlackRock Inc0.79%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atara Biotherapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncNovo Nordisk A/SGilead Sciences IncAbbott Laboratories

Data updated 2026-09-18.